Characterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Saito, Kosuke ^a   Uebanso, Takashi ^b   Maekawa, Keiko ^a   Ishikawa, Masaki ^a   Taguchi, Ryo ^a   Nammo, Takao ^b   Nishimaki Mogami, Tomoko ^a   Udagawa, Haruhide ^b   Fujii, Masato ^c   Shibazaki, Yuichiro ^c   Yoneyama, Hiroyuki ^c   Yasuda, Kazuki ^b   Saito, Yoshiro ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c Stelic Institute of Regenerative Medicine   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; LIPID; PHOSPHOLIPID; SPHINGOLIPID;

ANIMAL; CHEMISTRY; COMPLICATION; DISEASE MODEL; LIPID DIET; LIVER; LIVER CIRRHOSIS; METABOLISM; MOUSE; NONALCOHOLIC FATTY LIVER; PATHOLOGY;

ANIMALS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FATTY ACIDS; LIPIDS; LIVER; LIVER CIRRHOSIS; MICE; NON-ALCOHOLIC FATTY LIVER DISEASE; PHOSPHOLIPIDS; SPHINGOLIPIDS;

EID: 84939639945     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12466     Document Type: Article

References (40)

1. Browing, J. D. et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40, 1387-1395 (2004).
2. Yoshiike, N., Lwin, H. Epidemiological aspects of obesity and NASH/NAFLD in Japan. Hepatol. Res. 33, 77-82 (2005).
3. Zelber-Sagi, S., Nitzan-Kaluski, D., Halpern, Z., Oren, R. Prevalence of primary non-alcoholic fatty liver disease in a populationbased study and its association with biochemical and anthropometric measures. Liver Int. 26, 856-863 (2006).
4. Clark, J. M. The epidemiology of nonalcoholic fatty liver disease in adults. J. Clin. Gastroenterol. 40, S5-S10 (2006).
5. Bugianesi, E. et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123, 134-140 (2002).
6. Day, C. P., James, O. F. Steatohepatitis: a tale of two "hits"? Gastroenterology 114, 842-845 (1998).
7. Dowman, J. K., Tomlinson, J. W., Newsome, P. N. Pathogenesis of non-alcoholic fatty liver disease. QJM 103, 71-83 (2010).
8. Nehra, V., Angulo, P., Buchman, A. L., Lindor, K. D. Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig. Dis. Sci. 46, 2347-2352 (2001).
9. Puri, P. et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 50, 1827-1838 (2009).
10. Kurikawa, N. et al. A novel inhibitor of stearoyl-CoA desaturase-1 attenuates hepatic lipid accumulation, liver injury and inflammation in model of nonalcoholic steatohepatitis. Biol. Pharm. Bull. 36, 259-267 (2013).
11. Matsuzaka, T. et al. Elovl6 promotes nonalcoholic steatohepatitis. Hepatology 56, 2199-2208 (2012).
12. Han, X., Gross, R. W. Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom. Rev. 24, 367-412 (2005).
13. Taguchi, R., Nishijima, M., Shimizu, T. Basic analytical systems for lipidomics by mass spectrometry in Japan. Methods Enzymol. 432, 185-211 (2007).
14. Hu, C. et al. Analytical strategies in lipidomics and applications in disease biomarker discovery. J. Chromatogr. B 877, 2836-2846 (2009).
15. Zhao, C. et al. Integrated lipidomics and transcriptomic analysis of peripheral blood reveals significantly enriched pathways in type 2 diabetes mellitus. BMC Med. Genomics 6, S12 (2013).
16. Maekawa, K. et al. Global metabolomic analysis of heart tissue in a hamster model for dilated cardiomyopathy. J. Mol. Cell Cardiol. 59, 76-85 (2013).
17. Tajima, Y. et al. Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer's disease. Lipids Health Dis. 12, 68 (2013).
18. Fujii, M. et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med. Mol. Morphol. 46, 141-152 (2013).
19. Summers, S. A. Ceramides in insulin resistance and lipotoxicity. Prog. Lipid Res. 45, 42-72 (2006).
20. Teichgräber, V. et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat. Med. 14, 382-391 (2008).
21. Colombini, M. Ceramide channels and their role in mitochondria-mediated apoptosis. Biochim. Biophys. Acta. 1797, 1239-1244 (2010).
22. Shea, B. S., Tager, A. M. Sphingolipid regulation of tissue fibrosis. Open Rheumatol. J. 6, 123-129 (2012).
23. Ziobro, R., Henry, B., Edwards, M. J., Lentsch, A. B., Gulbins, E. Ceramide mediates lung fibrosis in cystic fibrosis. Biochem. Biophys. Res. Commun. 434, 705-709 (2013).
24. Listenberger, L. L. et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc. Natl. Acad. Sci. USA 100, 3077-3082 (2003).
25. Zammit, V. A. Hepatic triacylglycerol synthesis and secretion: DGAT2 as the link between glycaemia and triglyceridaemia. Biochem. J. 451, 1-12 (2013).
26. Dorn, C. et al. Expression of fatty acid synthase in nonalcoholic fatty liver disease. Int. J. Clin. Exp. Pathol. 3, 505-514 (2010).
27. Chakravarthy, M. V. et al. Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell 138, 476-488 (2009).
28. Liu, S. et al. A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use. Nature 502, 550-554 (2013).
29. Dreyer, C. et al. Positive regulation of the peroxisomal beta-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR). Biol. Cell 77, 67-76 (1993).
30. Higuchi, S. et al. IL-4 mediates dicloxacillin-induced liver injury in mice. Toxicol. Lett. 200, 139-145 (2011).
31. Avar, I., Kelava, T., Pravdi, D., Ulo, F. Anti-thromboxane B2 antibodies protect against acetaminophen-induced liver injury in mice. J. Xenobiotics 1, e8 (2011).
32. Yu, J. et al. COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator. Hepatology 43, 826-836 (2006).
33. Williams, C. S., Mann, M., DuBois, R. N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18, 7908-7916 (1999).
34. Cheng, A. S. et al. Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. Mod. Pathol. 17, 1169-1179 (2004).
35. Berridge, M. J. Inositol trisphosphate and diacylglycerol as second messengers. Biochem. J. 220, 345-360 (1984).
36. Jeong, D. H. et al. Subcellular redistribution of protein kinase C isozymes is associated with rat liver cirrhotic changes induced by carbon tetrachloride or thioacetamide. J. Gastroenterol. Hepatol. 16, 34-40 (2001).
37. Di Sario, A. et al. Selective Na+/H+ exchange inhibition by cariporide reduces liver fibrosis in the rat. Hepatology 37, 256-266 (2003).
38. Lieber, C. S., DeCarli, L. M., Mak, K. M., Kim, C. I., Leo, M. A. Attenuation of alcohol-induced hepatic fibrosis by polyunsaturated lecithin. Hepatology 12, 1390-1398 (1990).
39. Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-1321 (2005).
40. Taguchi, R., Ishikawa, M. Precise and global identification of phospholipid molecular species by an Orbitrap mass spectrometer and automated search engine Lipid Search. J. Chromatogr. A 1217, 4229-4239 (2010).